John David Scott, Allyson Lynn Hale, Tracy Zvenyach, Joseph Nadglowski, Lisa Renee Hilton
{"title":"Obesity treatment access in the United States: a state-level scorecard.","authors":"John David Scott, Allyson Lynn Hale, Tracy Zvenyach, Joseph Nadglowski, Lisa Renee Hilton","doi":"10.1016/j.soard.2026.09.020","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Obesity affects more than 40% of U.S. adults and carries substantial morbidity and mortality, yet access to evidence-based treatment varies widely across jurisdictions.</p><p><strong>Objectives: </strong>To evaluate and compare state-level access to evidence-based obesity treatment across the United States using a standardized composite framework.</p><p><strong>Setting: </strong>50 U.S. states and the District of Columbia (51 jurisdictions).</p><p><strong>Methods: </strong>Ecological cross-sectional study using publicly available policy and administrative data aggregated in 2026; the unit of analysis was the jurisdiction and no individual patient-level data were used. The Obesity Treatment Access Scorecard was derived from 44 metrics across 6 weighted tiers, coverage, access barriers, workforce capacity, regulatory factors, patient context, and treatment utilization, yielding scores of 0-100 mapped to letter grades (A-F). Data were verified by expert review with multisource validation, and sensitivity analyses tested alternative tier-weighting schemes.</p><p><strong>Results: </strong>Scores ranged from 25.5 to 77.7 (mean, 48.5; standard deviation [SD], 12.8). No state achieved an A grade (≥80). Fifteen jurisdictions (29.4%) scored below 40 and 10 (19.6%) scored 60 or higher. Massachusetts (77.7) and Minnesota (76.4) ranked the highest; Arkansas (25.5), Oklahoma (28.5), and West Virginia (28.9) ranked the lowest. Mean scores were highest in the Northeast (62.7 [SD, 10.2]) and lowest in the South (39.9 [SD, 10.5]). Variability was greatest in the patient context and workforce capacity tiers. Jurisdiction rankings were robust to alternative tier-weighting schemes (Spearman ρ ≥ .99).</p><p><strong>Conclusions: </strong>Access to evidence-based obesity treatment is highly variable across the United States, with no state achieving top performance. These findings highlight significant geographic disparities and support the need for policy and system-level reforms. The Obesity Treatment Access Scorecard is presented as an exploratory benchmarking framework requiring further validation before use in policy evaluation.</p>","PeriodicalId":94216,"journal":{"name":"Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.soard.2026.09.020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Obesity affects more than 40% of U.S. adults and carries substantial morbidity and mortality, yet access to evidence-based treatment varies widely across jurisdictions.
Objectives: To evaluate and compare state-level access to evidence-based obesity treatment across the United States using a standardized composite framework.
Setting: 50 U.S. states and the District of Columbia (51 jurisdictions).
Methods: Ecological cross-sectional study using publicly available policy and administrative data aggregated in 2026; the unit of analysis was the jurisdiction and no individual patient-level data were used. The Obesity Treatment Access Scorecard was derived from 44 metrics across 6 weighted tiers, coverage, access barriers, workforce capacity, regulatory factors, patient context, and treatment utilization, yielding scores of 0-100 mapped to letter grades (A-F). Data were verified by expert review with multisource validation, and sensitivity analyses tested alternative tier-weighting schemes.
Results: Scores ranged from 25.5 to 77.7 (mean, 48.5; standard deviation [SD], 12.8). No state achieved an A grade (≥80). Fifteen jurisdictions (29.4%) scored below 40 and 10 (19.6%) scored 60 or higher. Massachusetts (77.7) and Minnesota (76.4) ranked the highest; Arkansas (25.5), Oklahoma (28.5), and West Virginia (28.9) ranked the lowest. Mean scores were highest in the Northeast (62.7 [SD, 10.2]) and lowest in the South (39.9 [SD, 10.5]). Variability was greatest in the patient context and workforce capacity tiers. Jurisdiction rankings were robust to alternative tier-weighting schemes (Spearman ρ ≥ .99).
Conclusions: Access to evidence-based obesity treatment is highly variable across the United States, with no state achieving top performance. These findings highlight significant geographic disparities and support the need for policy and system-level reforms. The Obesity Treatment Access Scorecard is presented as an exploratory benchmarking framework requiring further validation before use in policy evaluation.